Breaking News

Xellia in Antibiotics Development Alliance

February 26, 2013

Aims to develop new antibiotics targeting Gram-negative bacteria

Xellia Pharmaceuticals, SINTEF Materials and Chemistry, and the Statens Serum Institut, have entered a collaboration agreement to develop new antibiotics effective against multi-drug resistant (MDR), Gram-negative bacteria. The four-year project is being supported by a $3 million grant from the Research Council of Norway (NFR), and also includes contributions from labs across Europe.
 
Xellia aims to develop new antibiotics that target Gram-negative bacterial infections, caused by Pseudomonas, Klebsiella, Acinetobacter and Enterobacter species. Pan-drug resistant (PDR) and extensively drug resistant (XDR) Gram-negative bacteria are becoming more common. Currently there are only two antibiotic subclasses available to treat XDR infections, polymyxins and tigecycline.
 
Dr. Aleksandar Danilovski, vice president of R&D at Xellia, said, “As the world’s leading supplier of both polymyxin B and colistin, Xellia has the experience and capability to develop new, polymyxin-like drugs with less side-effects. These drugs have the potential to address the immediate global need for antibiotics to overcome MDR infections, in particular those caused by PDR and XDR Gram-negative bacteria.”
 
Carl-Åke Carlsson, chief executive officer of Xellia, said, “I am convinced that with Xellia’s intellectual resources, and its decades of pharmaceutical developmental and manufacturing experience, we can make substantial progress in meeting this challenge. If successful, the results for patients of these infections and the potential market for these new drugs could be huge. This is a great opportunity to develop new drugs where there is an immediate and pressing medical need.”
  • API Sourcing Trends

    Kristin Brooks, Contract Pharma||April 11, 2016
    Drug product complexities, quality and regulatory hurdles drive market shift

  • Setting a Precedent for Biosimilars in the U.S.

    Setting a Precedent for Biosimilars in the U.S.

    Kristin Brooks, Contract Pharma||May 19, 2015
    Niall Dinwoodie of Charles River discusses several key industry issues on biosimilars and addresses some of the development and regulatory hurdles that remain

  • API Sourcing Trends

    API Sourcing Trends

    Kristin Brooks, Contract Pharma||March 19, 2015
    Ed Price of PCI Synthesis addresses trends, regulatory and supply chain hurdles, and quality concerns

  • Limiting APIs in Manufacturing Effluent

    Limiting APIs in Manufacturing Effluent

    Joan Tell, Robert Drinane, Bruce Naumann, Jessica Vestel, and Gregory Gagliano, Merck & Co., Inc.||June 2, 2016
    An approach for setting limits on pharmaceuticals discharged in manufacturing effluent

  • Biopharma CMO Market Trends

    Biopharma CMO Market Trends

    Tim Wright, Editor||June 2, 2016
    Continued strong growth in biopharma industry is being driven by biosimilars

  • Continuous Pharmaceutical Processes and Their Demands

    Continuous Pharmaceutical Processes and Their Demands

    Girish Malhotra, EPCOT International||April 5, 2016
    A look at the unique characteristics of continuous processes in pharmaceutical manufacturing.